Kyle LaHucik
FierceBiotech
Chicago, IL, United States
Contact Kyle
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Kyle:
'Stay alive': Wave of layoffs crashes into biotech startup inferno
You could call it survival of the fittest or the law of the jungle. | At least 30 biopharmas have announced layoffs since September 2021, and the wave is likely to continue as thousands of startups struggle to stay above the competition. → Read More
'Biotech sisterhood': 25 female CEOs find new ways to 'sponsor' the next generation at Arizona retreat
During a multihour hike in the hills of Arizona interspersed with cactus lessons, female CEOs fostered a "biotech sisterhood" aimed at lifting up their peers in the industry. → Read More
AbbVie, eyeing shift to endemic, adds to COVID-19 work with Scripps partnership
AbbVie is adding to its COVID-19 work in the hopes of developing new antivirals that can aid the shift from pandemic to endemic. | AbbVie and Scripps Research will work together to make new antiviral treatments for COVID-19 to fill what the Big Pharma says are gaps in patient needs as the pandemic heads toward the endemic phase. → Read More
Intellia's CRISPR-engineered cell therapy secures FDA orphan drug status after AML trial launch
Intellia Therapeutics' CRISPR-powered T cell therapy, which uses the gene editing method to reprogram a sample of the patient's immune cells, has → Read More
Fierce Medtech's 2021 Fierce 15
In one way or another, the Fierce 15 has always been about celebrating those who are finding new ways of doing things, whether it’s innovators creating novel treatments for patients in need or developers wielding the latest technologies to reinvent standard healthcare practices. → Read More
Roche plans 4-year late-stage trial for Alzheimer's candidate while awaiting crucial H2 readout
Roche is gearing up for a four-year phase 3 study of its Alzheimer's drug gantenerumab. | Roche is gearing up for a four-year phase 3 study of its Alzheimer's drug gantenerumab, and one trial site in Florida confirmed to Fierce Biotech that patient screening has already gotten underway for the trial, slated to begin June 24. → Read More
FDA slaps hold on Finch's C. diff med to get info on COVID-19 screening for donor-derived therapy
Finch Therapeutics' phase 3 trial for a Clostridioides difficile med has been placed on clinical hold by the FDA as the agency requests more information on how the biotech screens the donor-de → Read More
Russian invasion of Ukraine could affect more than 200 clinical trials across biotech and pharma
Russia's invasion of Ukraine is likely to impact millions of people, not just in the Eastern European nation but around the world as drug developers might face delays in clinical trials conducted i → Read More
Adagio CEO resigns with no explanation and the biotech plans COVID-19 antibody analysis this quarter
Adagio Therapeutics, attempting to bring COVID-19 treatments to market after raising a massive haul of capital during the pandemic, will have to go soul searching as its CEO is out the door with no → Read More
Ligand to spin off J&J-partnered antibody unit with $70M in funding
Ligand Pharmaceuticals will spin off its Johnson & Johnson-partnered antibody platform business OmniAb and capitalize the company with $70 million. | Ligand Pharmaceuticals will spin off its Johnson & Johnson-partnered antibody platform business OmniAb and capitalize the company with $70 million. → Read More
'Early stage': Majority of biotechs don't disclose ESG practices, but most plan to in near term
The biotech industry has not caught the ESG bug that has swept across C-suites in recent years as part of the broad push for corporate social responsibility. | The biotech industry has not caught the ESG bug that has swept across C-suites in recent years as part of the broad push for corporate social responsibility, according to a survey and review from life sciences law firm Fenwick. → Read More
With $1.7T in the coffers, biopharma M&A expected to be 'a different animal' in 2022
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms. Example: +water -Europe → Read More
Ex-FDA interim chief Giroir rejoins biotech world with eyes on $50M fundraising for new infectious disease company
Former FDA Acting Commissioner and Admiral Brett Giroir, M.D., is back in the private sector and jumping into securing a series A for his latest biotech. Altesa BioSciences, which broke cover Thursday, builds upon the work of the Emory scientists behind Merck's COVID-19 antiviral molnupiravir and a billion-dollar HIV treatment. → Read More
Editas suddenly terminates Chief Medical Officer Lisa Michaels without explanation
Editas Medicine has fired Chief Medical Officer Lisa Michaels, M.D., just 15 months into her tenure at the gene editing company. → Read More
CVS to bring late-stage clinical trials to certain locations in push to serve underrepresented patients
The next time you stop at CVS Health to pick up prescriptions, you might run into people entering a clinical trial or being recruited for one. The nationwide health network is teaming up with virtual trials provider Medable to enroll people into late-stage clinical studies. → Read More
'Not afraid of not transacting': SPAC appetite sharply declines in larger battering of biotech stocks
Fewer biotechs are merging with special purpose acquisition companies as drug developers get more "realistic and pragmatic" about the market. → Read More
J&J's Janssen inks $1B biobucks pact for Mersana's ADC tech in 3 targets
Johnson & Johnson's Janssen unit will pay $40 million upfront and up to $1 billion in biobucks for access to Mersana Therapeutics' antibody-drug conjugate tech for three targets. Following their preclinical collaboration, Janssen will handle clinical trials and commercialization. → Read More
Dewpoint, with a handful of Big Pharma partners from Merck to Pfizer, collects $150M to advance its 20 programs
Pfizer, Merck, Bayer and Volastra have already partnered with Dewpoint Therapeutics across neuromuscular conditions, HIV, cancer metastasis and cardiopulmonary diseases. Now, the Boston biotech has an additional $150 million to bankroll 20 pipeline programs. → Read More
J&J discontinues work on eczema drug, leading to $610M in impairment charges for ex-XBiotech asset
Johnson & Johnson said it will discontinue development of bermekimab in atopic dermatitis, which it paid $750 million for, but it will continue investigating the monoclonal antibody in another skin disease. → Read More
Biogen checks 'yes' with $30M opt-in on Roche's lymphoma bispecific as regulatory filings get underway for FDA, EU
Biogen and Roche's Genentech are looking to follow up on their multidecade history of getting medicines approved together, with the Aduhelm maker dishing out $30 million in the latest attempt. → Read More